Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 01, 2022

SELL
$3.12 - $7.52 $370,780 - $893,676
-118,840 Closed
0 $0
Q1 2022

May 04, 2022

SELL
$6.26 - $14.42 $7.43 Million - $17.1 Million
-1,186,799 Reduced 90.9%
118,840 $859,000
Q4 2021

Feb 07, 2022

BUY
$11.35 - $21.18 $453,341 - $845,971
39,942 Added 3.16%
1,305,639 $17.7 Million
Q3 2021

Nov 02, 2021

BUY
$18.17 - $24.7 $3.01 Million - $4.09 Million
165,617 Added 15.05%
1,265,697 $26.5 Million
Q2 2021

Aug 03, 2021

BUY
$20.08 - $29.02 $823,561 - $1.19 Million
41,014 Added 3.87%
1,100,080 $26.3 Million
Q1 2021

May 04, 2021

BUY
$27.0 - $32.48 $10.6 Million - $12.8 Million
392,629 Added 58.91%
1,059,066 $31 Million
Q4 2020

Feb 01, 2021

BUY
$26.68 - $38.23 $17.8 Million - $25.5 Million
666,437 New
666,437 $19.9 Million

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $55.1M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.